13F Holdings
中文EN

PAHC PHIBRO ANIMAL HEALTH CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 1069899 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.1%
TTM net income YoY51.5%
TTM EPS YoY49.7%
Revenue 3-yr CAGR16.4%
Net income 3-yr CAGR70.5%

Margins

Gross margin33.8%
Operating margin12.5%
Net margin6.7%
FCF margin1.4%
EBITDA margin15.9%

Returns

ROE28.2%
ROA7.1%
ROIC (approx.)15.6%
Asset turnover1.06x

Leverage & solvency

Liabilities / assets72.4%
Debt / equity1.46x
Current ratio3.20x
Interest coverage4.18x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio1.2%
Payout ratio19.0%
Capex / revenue4.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$1.52B$1.30B$1.02B$977.89M$942.26M
Cost of revenue$1.01B$896.27M$704.59M$679.65M$656.86M
Gross profit$512.51M$399.94M$313.09M$298.24M$285.40M
R&D expense$24.55M$23.73M$29.19M$24.39M$20.83M
SG&A expense$318.12M$289.48M$259.78M$226.39M$206.41M
Operating income$194.40M$110.47M$53.31M$71.85M$78.99M
Interest expense$46.42M$37.22M$23.01M$18.68M$12.69M
Pretax income$137.35M$67.99M$10.92M$54.07M$72.33M
Income tax$37.63M$19.73M$8.50M$21.46M$23.15M
Net income$99.72M$48.26M$2.42M$32.61M$49.17M
EBITDA$245.91M$156.07M$89.49M$105.86M$111.69M
EPS (basic)2.461.190.060.811.21
EPS (diluted)2.431.190.060.811.21
Dividends declared per share0.480.480.480.480.48
Weighted avg. shares (diluted)40.96M40.68M40.52M40.50M40.50M
Banking
Net interest income———-$15.32M-$11.88M
Balance sheet
Cash & equivalents$61.42M$68.04M$70.61M$41.28M$74.25M
Short-term investments$20.57M$9.00M$44.00M$40.00M$17.00M
Receivables$238.79M$227.98M$169.45M$163.48M$166.54M
Inventory$534.88M$444.43M$265.91M$277.57M$259.16M
Current assets$935.51M$810.61M$601.00M$585.72M$566.23M
PP&E, net$369.17M$354.69M$203.30M$195.57M$165.49M
Goodwill$60.05M$59.65M$54.56M$53.27M$53.23M
Intangibles$30.05M$36.47M$45.03M$54.99M$63.86M
Total assets$1.50B$1.36B$982.18M$971.40M$931.70M
Current liabilities$316.47M$293.47M$204.15M$176.00M$190.83M
Short-term debt$25.02M$16.25M$29.80M$22.30M$15.00M
Long-term debt$591.77M$615.43M$282.29M$311.54M$272.93M
Total debt$616.79M$631.68M$312.08M$333.84M$287.93M
Total liabilities$1.12B$1.08B$725.54M$688.89M$669.26M
Shareholders' equity$385.48M$285.68M$256.64M$282.51M$262.44M
Net debt$555.38M$563.65M$241.47M$292.56M$213.68M
Cash flow statement
Operating cash flow$68.95M$80.12M$87.59M$13.31M$31.65M
Capital expenditure$59.09M$38.29M$41.24M$51.79M$37.04M
Free cash flow$9.87M$41.83M$46.36M-$38.48M-$5.39M
Investing cash flow-$71.45M-$288.69M-$48.19M-$74.02M-$22.58M
Financing cash flow-$6.56M$207.13M-$6.77M$26.99M$16.34M
Depreciation & amortization$51.51M$45.60M$36.18M$34.01M$32.70M
Stock-based compensation$1.60M$717,000$475,000——
Dividends paid$19.46M$19.45M$19.44M$19.44M$19.44M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.